Abiopharma

🔍 Boyd William M III (Executive)

Company: Symbotic Inc. (SYM)

Report Date: 2026-04-23

Detailed Transactions and Holdings:

• Acquired 2,909 shares of Class A Common Stock (Direct)
  Date: 2026-04-23 | Code: M | equity_swap_involved: 0 | shares_owned_after: 65,136.00 | transaction_form_type: 4 | Footnotes: F1, F2
• Acquired 6,285 shares of Class A Common Stock (Direct)
  Date: 2026-04-23 | Code: M | equity_swap_involved: 0 | shares_owned_after: 71,421.00 | transaction_form_type: 4 | Footnotes: F1
• Sold 4,080 shares of Class A Common Stock at $58.0978 per share (Direct)
  Date: 2026-04-27 | Code: S | equity_swap_involved: 0 | shares_owned_after: 67,341.00 | transaction_form_type: 4 | Footnotes: F3, F4
• Sold 2,470 shares of Class A Common Stock at $58.7062 per share (Direct)
  Date: 2026-04-27 | Code: S | equity_swap_involved: 0 | shares_owned_after: 64,871.00 | transaction_form_type: 4 | Footnotes: F3, F5
• Sold 2,644 shares of Class A Common Stock at $59.7882 per share (Direct)
  Date: 2026-04-27 | Code: S | equity_swap_involved: 0 | shares_owned_after: 62,227.00 | transaction_form_type: 4 | Footnotes: F3, F6
• Sold 2,909 shares of Restricted Stock Units (Derivative)
  Date: 2026-04-23 | Code: M | equity_swap_involved: 0 | shares_owned_after: 8,728.00 | transaction_form_type: 4 | Footnotes: F7, F8, F8
• Sold 6,285 shares of Restricted Stock Units (Derivative)
  Date: 2026-04-23 | Code: M | equity_swap_involved: 0 | shares_owned_after: 43,995.00 | transaction_form_type: 4 | Footnotes: F7, F9, F9

Footnotes:

• F1: Restricted stock units convert into Class A common stock on a one-for-one basis.
• F2: Includes 548 shares acquired on February 27, 2026 under the Symbotic Inc. 2022 Employee Stock Purchase Plan in transactions that were exempt under both Rule 16b-3(d) and Rule 16b-3(c).
• F3: This transaction was executed pursuant to a trading plan entered into by the Reporting Person on August 19, 2025, in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934, as amended.
• F4: In accordance with SEC guidance authorizing aggregate reporting of same-day purchases and sales, the shares were sold in multiple transactions at prices ranging from $57.36 to $58.35, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
• F5: In accordance with SEC guidance authorizing aggregate reporting of same-day purchases and sales, the shares were sold in multiple transactions at prices ranging from $58.36 to $59.35, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
• F6: In accordance with SEC guidance authorizing aggregate reporting of same-day purchases and sales, the shares were sold in multiple transactions at prices ranging from $59.48 to $60.10, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
• F7: Each restricted stock unit represents a contingent right to receive one share of the Issuer's Class A common stock.
• F8: On January 23, 2024, the Reporting Person was granted 34,908 restricted stock units that vest as follows: 1/3 of the restricted stock units vest on January 23, 2025, and 1/12 of the restricted stock units vest quarterly thereafter, subject to the Reporting Person continued service with the Issuer on the applicable vesting dates.
• F9: On January 23, 2025, the Reporting Person was granted 75,416 restricted stock units that vest as follows: 1/3 of the restricted stock units vest on January 23, 2026, and 1/12 of the restricted stock units vest quarterly thereafter, subject to the Reporting Person continued service with the Issuer on the applicable vesting dates.